Category: Fellows Posters
To estimate the cost saving in MM therapy attributable to clinical trials (CT) in a Spanish tertiary hospital during the period 2016-2017.
The development of checkpoint inhibitors-based immunotherapy has completely changed the therapeutic approach of metastatic melanoma (MM). Moreover, the research activity about this tumor continues at a very high level through a large number of active industry-funded clinical trials.
Observational, retrospective study that considers those CT financed by a sponsor. The standard therapy (ST) comparison was chosen for each trial according to the Investigator´s brochure and NCCN (National Comprehensive Cancer Network) Guidelines.
The duration of ST was equated with the time of permanence of the subject in the trial. It was estimated the number of days of treatment (in oral therapy) or complete cycles received (intravenous therapy) of ST. The dose of ST was established according to body surface area or weight at recruitment to trial. The costs of ST were estimated using hospital-specific tender price and the US Dollar/Euro exchange rate on 1 January of each year (2016: 1.0978 US Dollar/Euro and 2017: 1.0522 US Dollar/Euro). It was considered a maximum reuse of vials.
Limitation: We did not consider the cost of working in aseptic conditions and the cost of administering the drugs.
Eleven CT reached our inclusion criteria with a total of forty-seven patients treated. The estimated cost saving per year was: $ 888,812 (2016) and $ 846,336 (2017).
The therapeutic alternatives in MM that have high budget impact are: